Fundraising Fox
Antares Therapeutics
Cambridge, US · Founded 2025 · 101 employees on LinkedIn · 8 known investors
Find your way into Antares Therapeutics
Sign up to see every warm intro you have to Antares Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Antares Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Antares Therapeutics discovers and develops precision medicines, with a focus on small molecule therapies targeting previously undruggable oncology targets and other serious diseases. The company combines proprietary chemistry, target biology, and predictive sciences to advance drug candidates for cancer and other therapeutic areas.
Founders & leadership
Investors · 8
How we know: Atlas Venture's portfolio page · a partner's Signal profile · board seat on SEC Form D · funding news · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the company's own site · Lightspeed Venture Partners's portfolio page · funding news · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Vida Ventures's portfolio page · funding news · the VCSheet dataset · Not right? Tell us
How we know: the company's own site · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$70M disclosed across 2 rounds · 2025
▶$30MraisedMay 2025 · 35 investors · BiotechnologyRule 506(b)
- Andrew FedderExecutive Officer
- Menelas N. PangalosDirector
- Jeffrey AlbersDirector
- Keith FlahertyDirector
- Jean-Francois FormelaDirector
- Adam FriedmanExecutive Officer, Director
- Brian PiperExecutive Officer
- Shelley ChuDirector
- Offering amount
- $136.7M
- Amount sold
- $30M
- First sale
- May 2025
- Incorporated
- Corporation, Delaware, 2025
- Federal exemptions
- 06b
▶$40MraisedMar 2025 · 3 investors · BiotechnologyRule 506(b)
- Andrew FedderExecutive Officer, Director
- Adam FriedmanExecutive Officer, Director
- Brian PiperExecutive Officer, Director
- Offering amount
- $40M
- Amount sold
- $40M
- First sale
- Mar 2025
- Incorporated
- Corporation, Delaware, 2025
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as Antares Therapeutics.
In the news
Frequently asked questions
- What does Antares Therapeutics do?
- Antares Therapeutics discovers and develops precision medicines, with a focus on small molecule therapies targeting previously undruggable oncology targets and other serious diseases. The company combines proprietary chemistry, target biology, and predictive sciences to advance drug candidates for cancer and other therapeutic areas.
- Who are Antares Therapeutics's investors?
- Antares Therapeutics's investors include Atlas Venture, Lightspeed Venture Partners, Vida Ventures, Omega Funds, Tenmile, Abingworth, AlleyCorp, Biotechnology Value Fund.
- How much funding has Antares Therapeutics raised?
- Antares Therapeutics has disclosed $70M raised across 2 rounds.
- Where is Antares Therapeutics headquartered?
- Antares Therapeutics is headquartered in Cambridge, US.